NanoViricides Inc. (NNVC)

[changes_iv]

For Larry Zeitlin and Kevin Whaley of San Diego, the novel Ebola treatment that may have saved two American aid workers marked a long road toward drug development and a first step toward possible containment of the deadly disease.

“I’ve always enjoyed science and developed an interest in trying to use biotechnology to improve public health,” Zeitlin, 45, wrote in an email to U-T San Diego on Tuesday. “Almost all of our efforts are on diseases that haven’t been well addressed by pharmaceutical companies or on diseases where, when they have been addressed, they haven’t been addressed globally.”

He and Whaley are co-founders of the biotech firm Mapp Biopharmaceutical in Sorrento Mesa, which has only nine staff members.

The company’s compound ZMapp, a cocktail of plant-generated antibodies, was used last week in a desperate effort to stabilize Ebola victims Dr. Kent Brantly and missionary Nancy Writebol. It’s the product of intellectual curiosity, a humanitarian vision and tobacco plants.

Last week, Samaritan’s Purse, a North Carolina-based charity hosting Brantly and Writebol in Liberia, asked Mapp’s founders to provide their serum through a compassionate-use agreement.

Zeitlin was nervous about testing the product for the first time on humans, but said he was confident in the drug’s manufacturer and in the general safety of antibodies that target infectious diseases.

http://www.utsandiego.com/news/2014/aug/06/larry-zeitlin-kevin-whaley-mapp-ebola-serum/

"Some of these drugs look great in the test tube and in mice and primates," says Erica Saphire, a molecular biologist at Scripps Research Institute whose lab is studying the effectiveness of ZMapp. The drug is a cocktail of antibodies that attach to the virus or infected human cells, flagging them for destruction by the immune system and "locking" Ebola's viral machinery so that the virus can no longer invade healthy cells.

The EbolaCide will not attach to human cells but it will to Ebola virus structures to destroy them, in the trillions, in a matter of hours. It does not matter if the immune system of a human or animal host of Ebola is compromised or not since nanoviricides are designed to work independent from the immune system.

We have a new 5kg cGMP Pilot Plant operational that scientists are racing to get validated.

Already Dr. Eugene Seymour has stated that we would be able to handle the demand for EbolaCide...

NanoViricides, Inc. now has its own drug manufacturing facility that is capable of producing sufficient quantities of an anti-Ebola drug after it is developed, for combating Ebola epidemics.

If NNVC's new configuration for anti-Ebola cide resolves with >90% rescue of subject animals, a number already reported for other cides, you bet the WHO will be interested.~ BigKahuna

If Dr. Anil Diwan and his team are confident that the latest developed EbolaCide candidate will yield a > 90% rescue of subject animals (in-vivo), by all means they must pursue efficacy tests in a costly BSL-4 lab facility. How long will efficacy tests last? fourteen days? Will the USAMRIID be the government entity to test the most developed Ebolacide candidate? If so, has the USAMRIID come on board and is now working on compiling efficacy tests results and possibly composing their latest review of Ebolacide results, hence Dr. Seymour's email reply to nanopatent, "yes but more news are forthcoming..."



If EbolaCide results turn out to be smashing good (as we longs expect) it won't be WHO just knocking on our door in West Haven, CT, it will be West African leaders knocking on the WHO doors.

Let us all remember this, it will not be long when our 5kg cGMP Pilot Plant will be validated and when it does it will be producing FluCide for Clinical Trials (2015) in Australia and EbolaCide to ease the pain of the West African countries.

All of the above is speculation on my part but I am confident we are quietly advancing in both fronts, FluCide and EbolaCide! Get ready for the longest period of "good news" fireworks in the history of markets!